Proteogenomics

Quantum-Si Announces Presentations at ASMS and ESHG

Retrieved on: 
Vendredi, mai 31, 2024
Hardware, Other Health, Technology, Pharmaceutical, Oncology, General Health, Biometrics, Medical Devices, Genetics, Fitness & Nutrition, Biotechnology, Science, Alternative Medicine, Other Science, Research, Health, TPM1, Protein sequencing, Doctor of Philosophy, Protein, University, Biological Physics, Vimentin, Proteogenomics, Assistant, Cancer, Platinum, Society, ASMS, NGPS, TPM2, Mass spectrometry, Fine chemical

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced presentations at two upcoming industry conferences.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced presentations at two upcoming industry conferences.
  • Dr. Brian Reed, Head of Research at Quantum-Si will present at the European Society for Human Genetics (ESHG) annual meeting being held June 1-4, 2024.
  • At ESHG, Dr. Reed will discuss the expanding role of Next-Generation Protein Sequencing™ (NGPS) in advancing biological research by enabling any researcher to sequence proteins in their lab.
  • Presentation details are as follows:
    Authors: Gloria Shenykman, PhD and Natchanon Sittipongpittaya, both of the University of Virginia and Kenneth Skinner, PhD, Quantum-Si

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

Retrieved on: 
Jeudi, octobre 5, 2023
Drug repositioning, Health, UK Biobank, Biomarker, Drug development, Proteogenomics, Data, Proteomics, Safety, UKB, Kingdom of Poland, CV, AstraZeneca, GWAS, Gene, Protein, Publication, Drug discovery, Biobank, Volunteering, Genomics, Research, Sun, Vaccine, Pharmaceutical industry, Nature

The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.

Key Points: 
  • The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
  • Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples.
  • The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts.
  • “These landmark publications are a powerful demonstration of how next-gen proteomics can reveal crucial biological insights not seen with traditional genomics alone.

Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs

Retrieved on: 
Mardi, septembre 12, 2023
Proteogenomics, Population health, Epigenomics, HT, Genomics, Research, Proteomics, Protein, Gene, Disease, Vaccine

UPPSALA, Sweden, 12th September, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology.

Key Points: 
  • The Olink platform represents the cutting edge in proteomics technology, delivering exceptional sensitivity and specificity for protein biomarker measurement.
  • Eurofins Genomics joins a worldwide network of service providers that have adopted the Olink platform.
  • Eurofins Genomics is a recognized leader in providing multi-omics services covering genomics, transcriptomics, and epigenomics.
  • Now, with the addition of Olink technology, Eurofins Genomics will offer the most powerful proteomic technology available for a more thorough understanding of the intricate connections between genes, proteins, and diseases.

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Retrieved on: 
Mercredi, juin 7, 2023
Astral, Proteogenomics, Workflow, Mass spectrometry, Chromatography, Cancer, Proteome, Thermo Fisher Scientific, Genomics, Proteomics, Science, Plasma, Thermo, Area studies, Seer, IDS, SEER, Health, Disease, Orbitrap, Heating, ventilation, and air conditioning, Uranium mining

As part of the collaboration, Seer will establish the Seer Technology Access Center to showcase its latest product, the Proteograph XT Assay Kit, in combination with Thermo Fisher’s newest mass spectrometer, the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer (MS).

Key Points: 
  • As part of the collaboration, Seer will establish the Seer Technology Access Center to showcase its latest product, the Proteograph XT Assay Kit, in combination with Thermo Fisher’s newest mass spectrometer, the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer (MS).
  • The Seer Technology Access Center will address an important unmet need for researchers who do not have access to mass spectrometry, but wish to undertake deep unbiased proteomics studies, such as translational and genomics researchers performing population-scale studies with deep molecular profiling.
  • As part of the collaboration, Seer and Thermo Fisher will develop and optimize proteomics and proteogenomics workflows, including the integration of data and analysis protocols.
  • To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio.

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook

Retrieved on: 
Jeudi, mars 2, 2023
Proteomics, Operationalization, SCIEX, Seer, Science, Discovery Life, Proteogenomics, Publication, Investment, SP100, Growth, Video game, Pharmaceutical industry, Cryptocurrency

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022.
  • Gross profit, inclusive of grant and other revenue, was $2.3 million and gross margin was 50% for the fourth quarter of 2022.
  • Net loss was $22.5 million for the fourth quarter of 2022, as compared to $19.7 million for the corresponding prior year period.
  • Seer will host a conference call to discuss the fourth quarter and full year 2022 financial results on Thursday, March 2, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

Retrieved on: 
Mercredi, janvier 4, 2023
ETH, Fluid mechanics, Software, Partnership, Protein, Drug discovery, Transcriptome, Research, Proteogenomics, Phenotype, Disease, Genome, Plasma, Entrepreneurship, Proteome, Proteomics, Pharmaceutical industry, Fine chemical, Bruker

Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company.

Key Points: 
  • Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company.
  • Going forward, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US.
  • As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.
  • We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development.

Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

Retrieved on: 
Mercredi, janvier 4, 2023
Health, Technology, Software, General Health, Research, Science, ETH, Fluid mechanics, Software, Partnership, Protein, Drug discovery, Transcriptome, Research, Proteogenomics, Phenotype, Multimedia, Corporation, Genome, Plasma, Entrepreneurship, Proteome, Proteomics, Fine chemical, Bruker

Going forward, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US.

Key Points: 
  • Going forward, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US.
  • As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.
  • We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development.
  • I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high performance proteomics.

Mission Bio's Tapestri® Platform Used to Identify Hidden HIV-infected Cells in Nature Paper

Retrieved on: 
Vendredi, janvier 6, 2023
Harvard Medical School, MIT, Memory, MD, Research, Infection, HIV, Proteogenomics, DNA, Phenotype, SAN, Immunotherapy, Disease, Patient, Genome, Cell, Harvard University, Massachusetts General Hospital, MGH, Ragon Institute, Cone Health Women's Hospital, Hospital, Doctor of Philosophy, Vaccine, Brigham, Viremia, Medicine, Nature

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2023 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women's Hospital using Mission Bio's Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 (HIV-1)-infected immune cells that allow the virus to evade immune response. The team utilized Tapestri®'s proteogenomics capabilities to detect HIV DNA and corresponding surface markers on patients' memory CD4+ T cells for the first time, as well as to develop a fingerprint for latent infection that may guide new treatment approaches.

Key Points: 
  • Previous research has suggested that host immune cells can slowly deplete these reservoir cells, lending hope to the idea that immunotherapy approaches could someday be used to treat disease.
  • In the new paper, the Boston-based teams used single-cell proteogenomic profiling on the Tapestri® Platform to simultaneously evaluate HIV DNA and the phenotype of single unmanipulated, patient-derived cells.
  • "This new paper demonstrates the versatility of the Tapestri® Platform," said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio.
  • The paper, " Phenotypic signatures of immune selection in HIV-1 reservoir cells ," published on January 4 in Nature.

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Retrieved on: 
Mercredi, décembre 14, 2022
Xmap, RUO, Infection, Software, Science, Protein, Plasma, SCIEX, Proteogenomics, Cell biology, Biomarker, Research, Patient, SEER, Cancer, Health, Mass spectrometry, PEA, Seer, Disease, Government, Proteome, Genomics, Pathology, Multimedia, PGC, Safety, Proteomics, Neurodegeneration, Pharmaceutical industry, Luminex, Discovery

HUNTSVILLE, Ala., Dec. 14, 2022 /PRNewswire/ -- Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers. This innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph™ Product Suite, SCIEX LC-MS/MS systems, Olink® Proximity Extension Assay (PEA), and Luminex xMAP® platforms.

Key Points: 
  • "Our proteomic experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of leading-edge proteomic and proteo-genomic technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects."
  • Then, in September, Discovery announced it was the largest certified commercial service provider for the Olink PEA platform in the Americas.
  • Discovery offers a wide range of services, including genomics, proteomics, pathology, and cell biology.
  • Seer is a life sciences company developing transformative products that open a new gateway to the proteome.

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Retrieved on: 
Mercredi, décembre 14, 2022
Xmap, RUO, Infection, Software, Science, Protein, Plasma, SCIEX, Proteogenomics, Cell biology, Biomarker, Research, Patient, SEER, Cancer, Health, Mass spectrometry, PEA, Seer, Disease, Government, Proteome, Genomics, Pathology, PGC, Safety, Proteomics, Neurodegeneration, Pharmaceutical industry, Luminex, Discovery

HUNTSVILLE, Ala., Dec. 14, 2022 /PRNewswire/ -- Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers. This innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph™ Product Suite, SCIEX LC-MS/MS systems, Olink® Proximity Extension Assay (PEA), and Luminex xMAP® platforms.

Key Points: 
  • Discovery's proteomic service laboratories are now integrated with its market-leading short- and long-read genomic service laboratories and expansive global commercial biorepository of hyper-annotated biospecimens.
  • "Our proteomic experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of leading-edge proteomic and proteo-genomic technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects."
  • Then, in September, Discovery announced it was the largest certified commercial service provider for the Olink PEA platform in the Americas.
  • Seer is a life sciences company developing transformative products that open a new gateway to the proteome.